{
    "nct_id": "NCT03567642",
    "official_title": "Phase 1 Study of Combination Osimertinib, Platinum, Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers With Concurrent RB1 and TP53 Alterations",
    "inclusion_criteria": "* Written informed consent\n* Advanced biopsy-proven metastatic non-small cell lung cancer\n* Either have not started an EGFR TKI or may have started osimertinib within the last 9 weeks\n* Somatic activating mutation in EGFR in pre-treatment tumor biopsy or cfDNA\n* Evidence of a concurrent P53 alteration by IHC or NGS on pre-treatment tumor biopsy or cfDNA\n* Evidence of a concurrent RB1 alteration by IHC or NGS on pre-treatment tumor biopsy or cfDNA\n* Must have a site of disease amenable to repeat biopsy and be willing to undergo a biopsy during treatment\n* Measurable (RECIST 1.1) indicator lesion not previously irradiated\n* Karnofsky performance status (KPS) ≥ 70%\n* Age >18 years old\n* Ability to swallow oral medication\n* Adequate organ function\n\n  * AST, ALT ≤ 3 x ULN\n  * Total bilirubin ≤ 1.5x ULN\n  * Creatinine ≤ 1.5x ULN OR calculated creatinine clearance ≥ 60ml/min\n  * Absolute neutrophil count (ANC) ≥ 1000 cells/mm^3\n  * Hemoglobin≥8.0 g/dL\n  * Platelets ≥100,000/mm^3\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnant or lactating women\n* Started an EGFR TKI other than osimertinib or started osimertinib more than 9 weeks ago\n* Any radiotherapy within 1 week of starting treatment on protocol.\n* Any major surgery within 1 weeks of starting treatment on protocol.\n* Any evidence of active clinically significant interstitial lung disease\n* Continue to have unresolved > grade 1 toxicity from any previous treatment\n* Have pure small cell histology\n* Corrected QT interval using Fridericia's formula (QTcF)>475msec or any clinically significant (as deemed by the investigator) abnormalities in rhythm or conduction or morphology of the resting EKG.\n* Patients are to be excluded from cisplatin treatment arm if they meet any of the following criteria:\n* Creatinine clearance < 60 ml/min\n* Hearing impairment requiring assistive device\n* Neuropathy\n* The treating provider does not feel as though the patient should receive cisplatin",
    "miscellaneous_criteria": ""
}